|
In this episode of the IMF’s #AskDrDurie web series, Dr. Brian Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended. |
|||
Have a question? Submit it to [email protected] |
|||
|
IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]! |
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.
